Showing that dipeptidyl aminopeptidase IV (DAP IV, EC 3.4.14.4) is a reliable enzyme cytochemical marker of T lymphocytes has received much more attention'-10 than showing the reliability of dipeptidyl aminopeptidase II (DAP II, EC 3.4.14.2) in haemic cells.2 10 Lojda2 first described the DAP II enzyme in blood lymphocytes in man.
Showing that dipeptidyl aminopeptidase IV (DAP IV, EC 3.4.14.4) is a reliable enzyme cytochemical marker of T lymphocytes has received much more attention '-10 than showing the reliability of dipeptidyl aminopeptidase II (DAP II, EC 3.4.14.2) in haemic cells.2 10 Lojda2 first described the DAP II enzyme in blood lymphocytes in man. This study describes the optimal conditions for showing cytochemically the presence of DAP II and IV in peripheral blood and bone marrow cells and the distribution of these enzymes in both normal and malignant haemic cells.
Material and methods
Heparinised peripheral blood buffy coats, bone marrow smears, and sheep erythrocyte rosetting lymphocyte preparations" were used. This investigation entailed 34 normal (controls) and 97 pathological Accepted for publication 18 March 1986 samples (Tables I and 2 ). The cytochemical demonstration of DAP II and DAP IV was performed according to the method of Lojda et al, 2 with slight modifications. The effect of fixation, substrate concentration, two coupling agents, two buffers, and conditions of incubation on the rate and intensity of the enzymatic reaction were studied. Controls included smears incubated without substrates or diazonium salts.
The following methods were found to give the best results for showing the presence of both enzymes: REAGENTS Fixative Formaldehyde vapour (formaldehyde solution 37-40% (w/v), BDH "Analar").
Substrates Lysyl-alanyl-4-methoxy-2-naphthylamide (LAMN) for DAP II, glycyl-prolyl-4-methoxy-2-naphthylamide (GPMN) for DAP IV (Bachem). Solvent Dimethylformamide (DMF) percentage of positivity in smears from various haematological disorders. Acute myeloid leukamia Activity of DAP II in leukaemic myeloblasts, monoblasts, proerythroblasts, megakaryoblasts varied (Table 1 ). The reaction pattern was either focal, scattered granular, or diffuse ( Figs. 1 and 2) . Four of the 26 myeloblastic leukaemia cases studied showed completely negative myeloblasts.
In a case of mixed acute myeloid leukaemia-that is, erythroid, myeloid, monocytic, megakaryocytic with eosinophilic, and basophilic components (? chronic myeloid leukaemia transformation)-all cell lineages exhibited the enzyme activity.
For DAP IV the leukaemic blasts showed no activity except in a single case of acute megakaryoblastic leukaemia, confirmed by platelet peroxidase ultracytochemistry and monoclonal antibody studies, where 3% of megakaryoblasts showed DAP IV scattered granular positivity. Systemic mastocytosis In a single case all mast cells showed scattered granular positivity for DAP II but were negative for DAP IV. Acute lymphoblastic leukaemia (ALL) Of the seven cases of ALL studied, five were identified as common ALL using monoclonal antibodies. The phenotype of the two other cases was not identified. DAP II activity in lymphoblasts varied considerably from complete negativity in one case (phenotype was not identified) to weak (less than 5%, two common ALL cases) or strong (55-96%, three cases of common ALL) positivity. The pattern of staining was either a localised (Fig. 3) or scattered granular positivity, but the localised pattern was more prominent. For DAP IV a small percentage of lymphoblasts (6%) was positive in three cases of common ALL while the remaining four cases of ALL were completely negative. B prolymphocytic leukaemia (B-PLL) In one case the prolymphocytes were completely negative for both DAP II and IV. Chronic lymphocytic leukaemia (CLL) The mean of positive lymphocytes was lower than that of the normal mixed T and B lymphocyte population of peripheral blood (Tables I and 2 ), but the degree of group.bmj.com on July 9, 2017 -Published by http://jcp.bmj.com/ Downloaded from Cytochemical study of DAP II and IV in normal and malignant haemic cells positivity varied widely between individual cases (Fig. 4) . With DAP IV the number of positive lymphocytes was almost always considerably reduced (Table 2 ). In one case of B-CLL, however, DAP IV positive lymphocytes were within the normal range among the buffy coat and bone marrow cells.
Further to this, we found few DAP IV positive lymphocytes (7%) in a case of suppressor T-CLL, while 40% of lymphocytes showed DAP II activitv. Hairy cell leukaemia (HCL) In 10 cases of hairy cell leukaemia the DAP II reaction pattern varied from focal to scattered granular positivity in hairy cells, although DAP IV activity was absent.
During an emerging remission of hairy cell leukaemia treated with human lymphoblastoid interferon (IFN-d) (Tables 1 and 2 ). In the case of severe invasion of bone marrow and peripheral blood by-non-Hodgkin's lymphoma the proportion of positive lymphoid cells was unchanged. As to DAP IV, however, lymphoid cells showed a considerable reduction in the number of positive lymphocytes (Table 2) . Multiple myeloma (MM) In the five cases studied most myeloma cells showed DAP II reactions, although they were completely devoid of DAP IV.
Plasma cell leukaemia (PCL) In the two cases most plasma cells exhibited scattered granular or focal cytoplasmic reaction patterns for DAP II while they were negative for DAP IV ( The results obtained with cytochemical tests on erythrocyte rosetting lymphocytes indicated that DAP II is present in T lymphocytes and also in some B lymphocytes, which supports previous findings.2 10 DAP IV activity seems to be confined to T lymphocytes; not all of them, however, exhibited the activity. This finding agrees with other studies on T and B lymphocyte subpopulations identified by rosetting techniques.4 5 Fewer bone marrow lymphocytes exhibited DAP II and IV activity compared with peripheral blood lymphocytes, which probably reflects the higher percentage of B cells in the bone marrow15 compared with those in the peripheral blood.
In seven cases of ALL a wide variation in DAP II activity was found, with all lymphoblasts in one case being totally negative. For DAP IV four cases of common ALL did not exhibit any activity in the lymnphoblasts, while the remaining three cases exhibited DAP IV positivity in a few lymphoblasts.
In B-CLL DAP II activity was variable, ranging from 21% to 93% but no diagnostic pattern was discernible. This contrasts with the findings for DAP IV: the present study and previous reports2 10 have shown that in B-CLL the number of positive lymphocytes is greatly reduced. The low percentage of positively reacting lymphocytes in these cases most probably represents residual T lymphocytes. Furthermore, we found considerably reduced activity of DAP IV in a case of suppressor T-CLL, a feature previously described by Crockard et al9 and reduced activity of DAP II as well, while Invernizzi et al°reported normal or appreciably increased DAP IV activity in two cases of helper T-CLL. This difference may be of value in discrimintting between helper and suppressor T cell disorders.
DAP II positivity was found in hairy cells of hairy cell leukaemia and in plasma cells of both multiple myeloma and plasma cell leukaemia. This differs from the findings of Invernizzi etal,'0 who reported that hairy cells were negative and that myeloma cells were only occasionally positive. This discrepancy is probably accounted for by the relatively long fixation time used by the authors. We found that a fixation time in excess of two minutes in formaldehyde vapour is inhibitory to DAP II. They also used fast garnet GBC as a coupling agent instead of the more suitable FBB, which has been shown to be the best in a comparative study using various diazonium salts, including fast garnet GBC. 6
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The lack of DAP IV activity in hairy cells and malignant plasma cells further supports the findings that lymphoid cells in B lymphoproliferative disorders do not show DAP IV activity.48 17 18 In this study a case of Sezary syndrome with an excess of circulating T helper cells showed DAP II activity without any DAP IV positivity. The finding of DAP IV positivity is in keeping with previous studies of four cases of Sezary syndrome.7 9 Whether this negativity of T lymphocytes in Sezary syndrome represents a difference in the level of differentiation is uncertain.
Interestingly, after six months of treatment a moderate number of DAP IV positive cells emerged in our patient with S&ary syndrome. This, perhaps, may have been due to an increase of non-Sezary cells of T lymphocyte origin, so DAP IV cytochemistry could possibly be used in the follow up and checking of response to treatment of these patients.
This study indicates that DAP II is present in normal lymphocytes, plasma cells, and macrophages. The enzyme is also found in most malignant haemic cells of most leukaemias, lymphomas, and multiple myelomas; thus it does not seem to be of much help in discriminating between various disorders. DAP IV is absent in B cell derived neoplasia-that is B-prolymphocytic leukaemia, B-chronic lymphocytic leukaemia, hairy cell leukaemia, multiple myeloma, and plasma cell leukaemia. In acute myeloid leukaemia blasts show no activity, except in megakaryoblastic leukaemia, in which only a few cells showed the reaction. The enzyme actuity is variable in Common ALL and when present, it represents a small percentage of cells. DAP IV cytochemistry may be useful in the follow up of patients with Sezary syndrome and hairy cell leukaemia.
